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Human immunodeficiency virus (HIV) has emerged as one of the leading causes of childhood mortality 
and morbidity in sub Saharan Africa. But, the attention given to HIV-infected children in terms of 
providing antiretroviral treatment (ART) had so far been ranked second. The study had the objectives of 
identifying predictors that had significant impacts on the survival status of HIV infected children who 
received antiretroviral treatment care in the University of Gondar Comprehensive Specialized Hospital, 
Gondar, Ethiopia. The data used in the study was based on secondary data from hospital records of HIV 
infected children aged below 15 years who started ART between 2008 and 2013 and who followed 
through April 2015 in University of Gondar Comprehensive Specialized Hospital, Gondar, Ethiopia. The 
Multivariable Cox Proportional model was fitted to identify factors affecting the survival of children after 
initiation of ART. The median survival time frame was found to be 55 months. At the end of the follow 
up, 46 (17.1%) children died due to the disease, the remaining 223 (82.9%) were alive and lost to follow-
up. The multivariate analysis of the Cox Regression model showed that the age of a patients (for age < 
1.5 years HR: 3.590 ; 95% CI: 1.439, 8.953; P = 0.006, baseline hemoglobin level (for hemoglobin level < 
7g/dl HR: 6.286; 95% CI: 2.328, 16.973; P=0.000, WHO clinical stage (For stage III HR: 0.308 ; 95% CI: 
0.150, 0.630; P = 0.001); and baseline CD4 count(HR: 0.180 ; 95% CI: 0.084, 0.388; P = 0.000) are 
significant factors of survival of HIV infected children during the 92 months of follow up. Therefore, 
special attention should be given to younger children in ART; patients with low CD4 cell count, patients 
with advanced WHO clinical staging (stage III and IV); and patients with low hemoglobin level to 
improve the survival of HIV infected children treated with ART.  
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INTRODUCTION 
 
The occurrence of the acquired immunodeficiency 
syndrome (AIDS) epidemic is amongst the forefront 
public health challenges that the world has faced 
(UNAIDS The Gap Report, 2014). It has had some strong 
emotional effects on individuals and families with the 
implications of untimely death along with medical, 
financial and social burdens for the past three decades. 
Millions     of     people    have     died     of    the    human 
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immunodeficiency virus (HIV) infection.  
Globally, an estimated 35 million (33.2 million to 37.2 
million) people were living with HIV in 2013 (Newell et al., 
2004). In sub-Saharan Africa, the number of AIDS-related 
deaths fell by 39% between 2005 and 2013. The region 
still accounted for 74% of all the people dying from AIDS-
related causes in 2013 (UNAIDS The Gap Report, 2014). 
There are 2.9 million (2.6 million to 3.2 million) children 
(aged 0 to 14) living with HIV in sub-Saharan Africa. Of 
the estimated 1.8 million people living with HIV, 1.5 
million were living in this region. There were also 190,000 
child deaths of AIDS-related illnesses during 2013, out of 
1.5 million people overall (WHO, 2014). Ethiopia is one of 
the sub-Saharan African countries hardly-hit by HIV/AIDS 
in all of its manifestations. In 2013, there were an 
estimated 793,700 (716,300-893,200) people living with 
HIV including 200,300 (172,400 to 232,400) children 
according to the EPP/Spectrum modelling (UNAIDS, 
2014 EPP/Spectrum).  
Tremendous progress has been made over the past 
few years in diagnosing and treating infants and children 
with HIV infection. However, much remains to be done to 
effectively scale up and sustain prevention efforts and 
treatment services for all in need. Treatment of HIV- 
infected children with Antiretroviral Therapy (ART) leads 
to immune reconstitution which results in an increase in 
CD4 lymphocyte counts, decreased risk of opportunistic 
infection and improved survival (UNAIDS The Gap 
Report, 2014; Newell et al., 2004). 
Moreover, children may die with an undetectable viral 
load and inadequate CD4 count recovery (Estimation and 
Project Package for HIV, 2014). However, very little 
attention has been given to how other factors, not relating 
to ART drugs, may influence the survival of HIV infected 
children. Therefore, this research is undertaken to 
explore the factors that have strong association with the 
survival experience of HIV-infected children treated with 
ART in the University of Gondar Comprehensive 
Specialized Hospital. 
The study had the objectives to assess the relationship 
of explanatory variables to survival time, estimate the 
survival duration and identify predictors that have 
significant impacts on the survival status of HIV infected 
children who received Antiretroviral Treatment and care 
in the University of Gondar Comprehensive Specialized 
Hospital, Gondar, Ethiopia. 
 
 
METHODOLOGY 
 
Study area, design, and period 
 
The data for the study were obtained from patients’ ART follow up 
records. During the study period, from the HIV  cohort  database,  a 
 
 
 
 
The data for the study were obtained from patients’ ART follow up 
records. During the study period, from the HIV cohort database, a 
total of 756 children were recorded. However, only 269 patients 
with a full record of variables who started ART between 2008 and 
2013 were included and continued until April 2015 in the University 
of Gondar Comprehensive Specialized Hospital. The data were 
collected based on the child’s identification number in HIV cohort 
database without any direct contact with a child so as to maintain 
the confidentiality of the child’s record. Demographic data, 
laboratory and clinical information of all children aged <15 years 
who started ART were included. 
 
 
Variables of the study 
 
The study focused only on demographic variables (age, and 
gender) and clinical/immunological variables (baseline weight, 
WHO Clinical Stage, Prophylaxis taken, baseline functional status, 
Baseline TB status, Reason for taking ART, baseline CD4 count, 
baseline hemoglobin levels, Opportunistic Illness) that can affect 
the survival time of HIV-infected children. The response variable in 
the study is the survival time of HIV-infected children measured in 
months after starting ART. This was measured according to the 
time a child had follow up from the time the child began to receive 
treatment until the time of an event (death) or lost to follow up (for 
those right censored subjects). 
 
 
Operational definitions 
 
(1) CD4 count is one of the factors used to determine when to start 
antiretroviral therapy (ART).  
(2) Threshold CD4 count: The CD4 cell count of a person who does 
not have HIV can be anything between 500 and 1500. People living 
with HIV who have a CD4 count over 500 are usually in pretty good 
health.  
 
 
Statistical model 
 
A variety of models and methods have been developed for doing 
this sort of survival analysis using either parametric or semi-
parametric approaches. One of the most popular types of 
regression models used in survival analysis is the Cox Proportional 
Hazard Model (Cox, D.R. Regression models and life Tables (with 
Discussion), 1972). The Cox Regression Model is used to 
determine which combinations of explanatory variables affect the 
form of the hazard function. Also the model is used to obtain an 
estimate of the hazard function for an individual who may be of 
interest. The Cox Regression Model can be used for data that 
contains censored observations. The model also takes into account 
the fact that the probability of experiencing an event differs with 
duration of exposure to risk. In particular we apply the semi-
parametric Cox proportional hazard model because it is the most 
commonly used model in hazard regression.   
 
 
RESULTS 
 
A total of 269 participants with full record of variables 
were included in the study. From this number, 46 (17.1%) 
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Table 1. Distribution of important socio-demographic and health factors of HIV infected children. 
 
Covariates  Category  Censored (%) Dead Total 
Age 
Age less than 1.5 years 19 (67.9%) 19 28 
Ages between 1.5-5 years 75 (78.1%) 21 96 
Ages between 5 - 14 years (the reference category) 129 (89.0%) 16 145 
     
Gender 
Male 92 (79.3%) 24 116 
Female 131(85.6%) 22 153 
     
Baseline functional status 
Working 124 (87.3%) 18 142 
Ambulatory 58 (85.3%) 10 68 
Bedridden 41 (69.5%) 18 59 
     
Baseline WHO stage 
Stage 1 44 (95.7%) 2 46 
Stage 2 59 (95.2%) 3 62 
Stage 3 72 (86.7%) 11 83 
Stage 4 48 (61.5%) 30 78 
     
Baseline CD4 count 
Above the threshold 120(93.0%) 9 129 
Below the threshold 103(73.6%) 37 140 
     
Original regimen 
D4T-3TC-NVP 85 (81.7%) 19 104 
D4T-3TC-EFV 8 (72.7%) 3 11 
AZT-3TC-NVP 102 (84.3%) 19 121 
AZT-3TC-EFV 9 (75.0%) 3 12 
Other drugs 19 (90.5%) 2 21 
     
Reason For ART 
Clinical 20 (87.0%) 3 23 
CD4 87 (77.7%) 25 112 
CD4 and clinical 80 (90.9%) 8 88 
CD4 and lymphocytes 36 (78.3%) 10 46 
     
Continuous Prophylaxis 
use 
No 68 (85.0%) 12 80 
Yes 155 (82.0%) 34 189 
Baseline 
TB Screen 
- ve 108 (84.4%) 20 128 
+ve 115 (81.6%) 26 141 
     
Opportunistic Illness 
No 102 (82.3%) 22 124 
Yes 121(83.4%) 24 145 
     
Base line  
hemoglobin level (gm/dl) 
≤7.00 gm/dl 76 (78.4%) 21 97 
7.00 to 8.50 gm/ dl 30 (73.2%) 11 41 
8.50 to10.00 gm/dl 43 (82.7%) 9 52 
> 10.00 gm/dl (reference category) 74 (93.7%) 5 79 
 
 
 
children died due to the disease, 223 (82.9%) were alive 
or loss to follow-up during the time of data collection. Out 
of the total 269 ART patients, 116 (36.65%) were male 
and the remaining were females. Among the 269 
children, 78 (30%) were at clinical stage IV, 82 (30.5%) 
were at clinical stage III, 63 (23.4%) were at clinical stage 
II and the rest which amount to 46 (17.1%) children were 
at clinical stage I when they started ART (Table 1). 
From the results of the Multivariate analysis using the 
significant variables found in Table 2, the covariates age, 
WHO clinical stages, CD4 counts and hemoglobin level 
are the  four  categorical  variables  that  are  found  to be  
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Table 2. Multivariate analysis using the significant variables in the equation. 
 
Variable B SE Wald df Sig. Exp (B) 
95.0% CI for Exp (B) 
Lower Upper 
Age - - 11.257 2 0.004 - - - 
Age(1) 1.278 0.466 7.513 1 0.006 3.590 1.439 8.953 
Age(2) 0.968 0.341 8.077 1 0.004 2.632 1.350 5.130 
Baseline WHO stage - - 24.502 3 0.000 - - - 
Baseline WHO stage (1) -2.443 0.744 10.794 1 0.001 0.087 0.020 0.373 
Baseline WHO stage (2) -1.890 0.623 9.192 1 0.002 0.151 0.045 0.513 
Baseline WHO stage (3) -1.179 0.366 10.370 1 0.001 0.308 0.150 0.630 
Baseline CD4 count -1.713 0.391 19.200 1 0.000 0.180 0.084 0.388 
Baseline hemoglobin - - 13.658 3 0.003 - - - 
Baseline hemoglobin (1) 1.838 0.507 13.158 1 0.000 6.286 2.328 16.973 
Baseline hemoglobin (2) 1.721 0.550 9.795 1 0.002 5.592 1.903 16.436 
Baseline hemoglobin (3) 1.633 0.600 7.406 1 0.007 5.119 1.579 16.593 
 
 
 
significantly associated with the survival time of HIV 
infected children under ATR treatment in the fitted Cox 
regression model. 
Let us begin with Baseline CD4 cell count of the patient 
that is supposed to be significant both clinically and 
statistically. In this study, a Baseline CD4 cell count has 
been found to have a significant impact on the survival 
time of HIV infected children. The estimated hazard ratio 
for baseline CD4 counts is 0.180 (with a 95% C.I. 0.084 
to 0.388). Thus, patients whose CD4 counts are above 
the threshold levels have an 82% lower risk of death than 
those whose CD4 counts are below the threshold levels. 
The confidence interval indicated that the risk of death for 
those patients that have CD4 counts above the threshold 
levels could be lower by 38.8% or as low as 8.4% than 
patients that have CD4 counts below the threshold levels 
(500 cells/mm
3
); p < 0.0001. 
HIV-infected children aged below 1.5 years are 3.59 
times more likely to die than children aged between 5 to 
14 years. The 95% C.I. confirmed that the hazard of 
death for this category could be as low as 1.439 and as 
high as 8.953 compared with children aged between 5 to 
14 years. HIV-infected children aged between 1.55 and 5 
years are 2.632 times more likely to die than children 
between the ages of 5 to 14 years. The 95% CI verified 
that the rate of death could be as small as 1.350 and as 
large as 5.130. HIV-infected children aged below 1.5 
years are 1.36 times more likely to die than HIV-infected 
children aged between 1.5 and 5 years given that all 
other factors are constant. 
The estimated risks of death for a patient with 
hemoglobin levels less than 7gm/dl as compared to those 
patients with hemoglobin levels greater than 10gm/dl 
(reference category) are 6.286 (95% CI: 2.323, 16.973). 
This means that the hazard rate of death of a child for a 
hemoglobin level less than 7gm/dl is 6.286 times more 
likely to die than HIV-infected children with hemoglobin 
level  greater   than  10gm/dl.  In  addition,  the  estimated 
relative risk (hazard ratio) of dying patients with 
hemoglobin levels between 7 to 8.5gm/dl are 5.592 times 
more likely to die as compared to those patients with 
hemoglobin level greater than 10gm/dl(reference 
category).  
The 95% C.I. suggests that the rate of death could be 
as low as 1.903 and as high as 16.436. Moreover, the 
estimated hazard ratio of hemoglobin levels between 8.5 
to 10gm/dl compared to the reference hemoglobin level is 
5.119 (95% CI: 1.579, 16.593). This implies that the risk 
of dying for patients with hemoglobin levels between 8.5 
to 10gm/dl is 5.119 times more likely to die than those 
patients with hemoglobin levels greater than 10gm/dl 
(reference category). Children with hemoglobin levels 
less than 7gm/dl are 1.124 times more likely to die than 
children with hemoglobin levels between 7gm/dl to 
8.5gm/dl. Moreover, children with hemoglobin levels 
greater than 10gm/dl are 84% less likely to die than 
children with hemoglobin value less than 7gm/dl provided 
that all other factors are held constant. 
The reference category for the design variables of 
WHO clinical stage is patients who are in the specified 
WHO clinical stage IV. The estimated hazard ratio for 
clinical stage III is 0.308 (with a 95% C.I. 0.15-0.630). 
Thus, the hazard of death for clinical stage III is 70% less 
likely than those of clinical stage IV. On the other hand, 
the estimated hazard ratio of stage III compared to stage 
II was 2.04 =                   )). Since the 
confidence interval does not contain 1, an individual in 
clinical stage III has a significantly higher hazard rate 
than patients in clinical stage II. Thus, patients in stage III 
are 2.04 times more likely to die than patients in stage II.  
 
 
Assessing the goodness of fit of the model 
 
The goodness of fit of the proportional hazard model was 
checked based  on  the  empirical data. Therefore, for the  
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Table 3. Likelihood ratio, score and wald tests for testing the global null 
hypothesis of   . Testing global null hypothesis:     
 
Test Chi-Square Df Pr>Chisq 
Likelihood ratio 78.647 9 <0.0001 
Score 74.786 9 <0.0001 
Wald 67.759 9 <0.0001 
 
Moreover, Cox-Snell residuals are used to assess the overall goodness of fit of 
the model.  
 
 
 
 
 
Figure 1. Cumulative hazard plot of the Cox-Snell residuals of the cox proportional 
hazards regression model. 
 
 
 
model fitted in this study, the Likelihood Ratio, Score and 
Wald tests were used to compare (at 5% significance 
level) the goodness of fit of the model. The SAS output in 
Table 3 revealed that the log partial likelihood function (-
2LL) without covariate was 489.281 while the function 
with significant covariates was 410.634. This result 
showed that the model is appropriate with a chi-square of 
78.647 with 9 degrees of freedom and a p-value of 
<0.0001. The plot in Figure 1 of the cumulative hazard 
function of the Cox-Snell residual against the Cox-Snell 
residuals are fairly close to the 45°
 
straight line through 
the origin. This suggested that the model fit to the data is 
satisfactory. The 45
0
straight line through the origin is 
drawn for reference. 
 
 
DISCUSSION 
 
This study identified variables/factors that are significantly 
associated with survival time of HIV-infected children 
under ART treatment. The results of this study showed 
that the risk of death among HIV infected children among 
the age groups of less than 1.5 years and 1.5 to 5 years 
are higher than those ages between 5 to 14 years. A 
study    by     Gebremedhin     et     al.    (2013)   identified 
independent predictors of children’s mortality on ART. 
The result suggested that the mortality of children on 
ART was low and factors that affect mortality of children 
on ART were among those children who were less than 
18 months of age.  
A similar study by Munyagwa et al. (2012) also found 
that mortality among HIV-infected children was highest 
among those aged less than 2 years. Thus, mortality 
among these high risk groups contributed to the higher 
rate of mortality. CD4 cell count is the most important 
marker of HIV disease progression and a strong predictor 
of the survival of HIV-infected children, similar to the 
plasma viral load. That may be due to the fact that HIV 
attacks CD4 cells, and as time elapses people with HIV 
often notice their CD4 cell counts drop. Hence, the lower 
the CD4 cell count the greater the chances of acquiring a 
number of very serious diseases. The significant impact 
of CD4 cell counts on patients’ survival rate has been 
acknowledged by many studies.  
A study by Brady et al. (2010), Lumbiganon et al. 
(2011) and Phongsamart et al. (2013) reported that HIV-
infected children with low baseline CD4 cell counts had a 
strong likelihood of early mortality. The results in this 
current study are also consistent with the findings in the 
above   studies.   But,   a   similar   study   conducted   by  
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(Habtamu and Eshetu, 2012) in Bahir-Dar found that low 
baseline CD4 cell counts was not a predictor of survival 
time of HIV infected children. His finding contradicts our 
findings that a low baseline CD4 cell counts were a 
strong risk factor for survival time of HIV infected 
children. 
The finding of this study observed that a higher risk of 
mortality was found among HIV-infected children with 
lower hemoglobin levels (anemic groups) compared to 
hemoglobin levels greater than 10gm/dl. This study was 
consistent with other studies conducted elsewhere. 
According to Ebissa et al. (2015), it was found that 
hemoglobin levels less than 7 gm/dl were significant 
independent predictors of death after controlling for other 
factors. For instance, another study also identified that 
the determinants of mortality in Bahir Dar showed that the 
risk of death is higher among HIV-infected children with a 
lower hemoglobin level [13]. Therefore, the above studies 
confirm the same conclusion as ours.   
Like CD4 cell counts, the WHO Clinical Staging system 
has been shown to be a practical and accurate way to 
manage HIV-infected patients. In this study, we found 
that the advanced WHO clinical stages III and IV were 
independent markers of mortality for patients on ART. 
The possible justification for the finding is that the 
advanced clinical stage of the disease is the cause for 
HIV-associated complications. A study in Lumbiganon et 
al. (2011) found that those children with WHO clinical 
stage IV had an increased risk of death. Similar to our 
findings, studies by Atnafu et al. (2012), Ebissa et al. 
(2015) and Adem et al. (2014) provided evidence that 
HIV infected children on ART in advanced clinical stages 
(III and IV) had a strong association with high mortality. 
The aforementioned sources showed that the most 
significant predictors of survival of children were CD4 
count, advanced WHO clinical stages, age, weight and to 
some extent opportunistic diseases like anemia and 
pneumonia. The findings of the current study identified 
and focused on advanced WHO clinical stage, age, 
hemoglobin level and baseline CD4 count as determinant 
predictors of survival of HIV-infected children who were 
treated with ART at the University of Gondar 
Comprehensive Specialized Hospital. Weight did not 
come out as a strong predictor although it is a clinically 
meaningful determining variable.  
 
 
Conclusions 
 
In this study, we tried to identify the factors that are 
associated with survival time of HIV infected children 
treated with ART in the University of Gondar 
Comprehensive Specialized Hospital using the methods 
of survival analysis. The Kaplan-Meier and log-rank test 
are used to estimate and compare the survival time of 
children after initiation of ART treatment. The study has 
shown that the overall median survival time of HIV 
infected   children    under   the   study  was 51.1 months. 
 
 
 
 
During the follow-up period, out of the 269 HIV infected 
children 46 (17.1%) of them experienced the event (that 
is, death).  
Moreover, the results of the multivariable proportional 
hazards Cox regression model showed that CD4 count at 
the start of ART, age, advanced WHO clinical stages and 
low hemoglobin level (less than 7gm/dl and between 7 to 
8.5gm/dl) are associated with a higher risk of mortality. 
And also HIV- infected children at ages less than 1.5 
years and ages between 1.5 to 5 years and who were at 
advanced WHO clinical stage III & IV are also associated 
with increased rate of mortality in both the univariable 
and multivariable analysis. Similarly, patients with poor 
health indicators like low baseline CD4 cell counts and 
low hemoglobin levels are less likely to survive. 
Therefore, special attention should be given to younger 
children in ART; children should start ART treatment at 
an early age, with CD4 cell counts at the normal level or 
above the threshold level and when they have higher 
hemoglobin values and when they are at a lower clinical 
stage. 
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